50 cents On the Horizon ?, page-1550

Agm 2016

Creating Clear Value Inflection Points in HIV-1 Program

•  Studies very carefully designed in conjunction with Key Opinion Leaders with industry feedback

• Specifically designed to show potential partners how BIT225 can be used in combination with current ART

•  - Phase2 HIV-1 Trial(BIT225-009)

•  Expect trial commencement shortly–Head line data expected in 3Q17
•  Expected outcome(s)–change of viral load in blood indicating impact on underlying viral reservoir, also impact on immune activation.

•  Analytical Treatment Interruption(ATI) Study–
•  Trial is underway evaluating BIT225 in HIV-1 Infected Humanised Mice-Data expectedQ1/17 •  Expected outcome(s)–impact on viral rebound once ART is stopped .

Both study approaches validated in discussions with potential partners


Viral load was higher in BIT225 patient group than placebo group in Phase2 HIV-1 Trial (BIT225-009) so indicating no impact on underlying viral reservoir.

Not sure what results were for humanised mice interruped after taking BIT225 and ART. Anyone know the results , were they mentioned anywhere.

It mentions both studies were validated in discussions with potential partners. I wonder what the partners are thinking about the results of these studies.